Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of SIM0270 + everolimus versus investigator's choice therapy after CDK4/6 inhibitor treatment in ER-positive/HER2-negative advanced or metastatic breast cancer
CTR20243876Phase 3Active
- Sponsor
- Simcere Zaiming
- Start
- Nov 2024
- Modality
- Small Molecules, Molecular Glues → Targeted Protein Degraders (TPDs) → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of SIM0270, everolimus, exemestane and fulvestrant in breast cancer (2 arms), sponsored by Simcere Zaiming. Primary endpoint: Progression-free survival by blinded independent radiologic review committee. Started Nov 2024; status: active.
02
Drugs
SIM0270everolimusexemestanefulvestrant
03
Conditions
breast cancer
Beyond the preview
Go deeper on CTR20243876.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20243876.